作者：E. Louise Thomas PhD, Jimmy D Bell PhD, Aidan Makwana M. Eng, Rexford Newbould PhD, Anil W. Rao PhD, Giulio Gambarota PhD, Paul M. Matthews MD, John D. Beaver PhD, Gary Frost PhD, Bruno Delafont MS, Rajesh G. Mishra MD, ,Evan S. Berk PhD, Susan M. Schwartz PhD。
作者单位：
E. Louise Thomas 博士、Jimmy D Bell博士：英国伦敦帝国理工学院代谢分子临床科学中心；
Aidan Makwana M.工程师、Rexford Newbould博士、Anil W. Rao博士、Giulio Gambarota 博士、Paul M.Matthews 医学博士、John D. Beaver 博士：英国伦敦葛兰素史克临床成像中心；
Gary Forst 博士：英国伦敦理工学院哈默史密斯医院营养和营养学研究小组；
Bruno Delafont 硕士：英国伦敦葛兰素史克公司生物识别部；
Rajesh G. Mishra 医学博士、Evan S. Berk博士、Susan M. Schwartz博士：美国新泽西葛兰素史克公司消费者保健部；
【摘自】欧洲临床营养杂志， 2011年11月第65期1256-1262。
【文献摘要】
背景和目的：众多研究发现，通过低热量低脂肪饮食，并结合奥利司他治疗，在相同的条件下，比安慰剂能够减少更多的体重。且这种减肥伴随着脂肪组织的重新分布。自60mg奥利司他可以作为OTC药物来使用后，本研究的目的主要是确定在一个运动员数量极少的社区中，奥利司他是否可以作为减肥的一个有效选择。
方法：通过核磁共振成像和核磁波普分析检测仪器分别测量27个受试者的脂肪组织和脂肪率，且在接下来的3个月通过60mg奥利司他并结合低热量低脂的饮食来进行治疗。
结果：观察到受试者的腹内脂肪组织减少了10.6%，皮下脂肪减少了11.7%，心包肥胖体积减少了9.8%，肝内脂肪减少了43.3%。这些身体脂肪含量分布变化的同时，也伴随着着血脂水平的改善和血压、心率的降低。
结论： 奥利司他60mg可有效降低体重、全身脂肪量、内脏脂肪量，并有降低肌间脂肪和肝脏脂肪的趋势。
【文献原文】
Pragmatic study of orlistat 60mg on abdominal obesity
Author: E. Louise Thomas PhDa, Aidan Makwana M. Engb, Rexford Newbould PhDb, Anil W. Rao PhDb, Giulio Gambarota PhDb, Gary Frost PhDc, Bruno Delafont MSe, Rajesh G. Mishra MD PhDf, Paul M. Matthews MD DPhilb,d, Evan S. Berk PhDf, Susan M. Schwartz PhDf, Jimmy D Bell PhDa, John D. Beaver PhDb
Author information：
G. Derosa MD PhD：Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy;
A.F.G. Cicero MD PhD; A.D’Angelo BD PhD; E. Fogari MD and P. Maffioli MD : Department of Internal Medicine, Aging and Kidney diseases, “G. Descovich” Atherosclerosis study Center, University of Bologna, Bologna, Italy.
Quote From: European Journal of Clinical Nutrition 65, 1256-1262(November 2011)
【ABSTRACT】
Background and Aims: It is well established combining a reduced calorie, low fat diet with the lipase inhibitor orlistat, results in significantly greater weight loss than placebo plus diet. This weight loss is accompanied by changes in adipose tissue (AT) distribution. Since 60mg orlistat is now available as an over-the-counter medication, the primary objective of this study was to determine whether 60mg orlistat is as effective a weight loss option in a free living community population with minimal professional input.
Methods: Adipose tissue and ectopic lipid content were measured using MRI and 1H MR Spectroscopy (MRS), respectively, in 27 subjects following 3 months treatment with orlistat 60mg and a reduced calorie, low-fat diet.
Results: Significant reductions in intra-abdominal AT (-10.6%, p=0.023) subcutaneous (-11.7% p<0.0001) and pericardial fat (-9.8%, p=0.034) volumes and intra-hepatocellular lipids (IHCL) (-43.3%, p=0.0003) were observed. These changes in body fat content and distribution were accompanied by improvements in plasma lipids and decreases in blood pressure and heart rate.
Conclusion: These findings suggest that over-the-counter 60 mg orlistat, in combination with the type of advice a subject could expect to be given when obtaining 60 mg orlistat in a community setting does indeed result in potentially clinically beneficial changes in body composition and risk factors for metabolic diseases.